WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 206477
CAS#: unknown as of 9/28/2015
Description: Pirotinib, also known as KBP-5209, is orally bioavailable inhibitor of the receptor tyrosine kinase (RTK) epidermal growth factor receptor (ErbB; EGFR) family, with potential antineoplastic activity. Upon administration, pirotinib selectively and irreversibly binds to and inhibits the epidermal growth factor receptors 1 (ErbB1; EGFR), 2 (ErbB2; HER2), and 4 (ErbB4; HER4). This may result in the inhibition of cell growth and angiogenesis in tumors overexpressing these RTKs. EGFRs play major roles in both tumor cell proliferation and tumor vascularization, and are overexpressed in many cancer cell types.
MedKoo Cat#: 206477
Name: Pirotinib
CAS#: unknown as of 9/28/2015
Chemical Formula:
Exact Mass:
Molecular Weight:
Elemental Analysis:
Pirotinib, is not in stock. This product may be available through custom synthesis when its structure is available.
Synonym: KBP-5209; KBP 5209; KBP5209; Pirotinib
IUPAC/Chemical Name: none
SMILES Code: none
The following data is based on the product molecular weight Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
